- Home
- HQH vs ESPR Comparison
HQH vs ESPR Comparison
Compare HQH & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQH | ESPR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 793.7M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HQH | ESPR |
|---|---|---|
| Price | $18.32 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 217.0K | ★ 3.4M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ 86.21 |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | ★ $332,314,000.00 |
| Revenue This Year | N/A | $27.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.54 | ★ N/A |
| Revenue Growth | N/A | ★ 185.66 |
| 52 Week Low | $13.77 | $0.73 |
| 52 Week High | $20.46 | $4.18 |
Technical Indicators
Market Signals| Indicator | HQH | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 41.62 |
| Support Level | $17.70 | $2.36 |
| Resistance Level | $19.57 | $3.02 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | -0.18 | -0.06 |
| Stochastic Oscillator | 16.02 | 34.93 |
Price Performance
Historical ComparisonAbout HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.